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Abstract: The COVID-19 pandemic caused by the SARS-CoV-2 coronavirus has stretched national 
testing capacities to breaking points in almost all countries of the world. The need to rapidly screen 
vast numbers of a country’s population in order to control the spread of the infection is paramount. 
However, the logistical requirement for reagent supply (and associated cost) of RT-PCR based 
testing (the current front-line test) have been hugely problematic. Mass spectrometry-based 
methods using swab and gargle samples have been reported with promise, but have not approached 
the task from a systematic analysis of the entire diagnostic process. Here, the pipeline from sample 
processing, the biological characteristics of the pathogen in human biofluid, the downstream bio- 
and physical-chemistry and the all-important data processing with clinical interpretation and 
reporting, are carefully compiled into a single high-throughput and reproducible rapid process. 
Utilizing MALDI-ToF mass spectrometric detection to viral envelope glycoproteins in a systems 
biology-multidisciplinary team approach, we have achieved a multifaceted clinical MALDI ToF MS 
screening test, primarily (but not limited to) SARS-CoV-2, with direct application to other future 
epidemics/pandemics that may arise. The clinical information generated not only includes SARS-
CoV-2 coronavirus detection–(Spike protein fragments S1, S2b, S2a peaks), but other respiratory 
viral infections detected as well as an assessment of generalised oral upper respiratory immune 
response (elevated total Ig light chain peak) and a measure of the viral immune response (elevated 
intensity of IgA heavy chain peak). The advantages of the method include; (1) ease of sampling, (2) 
speed of analysis, and much reduced cost of testing. These features reveal the diagnostic utility of 
MALDI-ToF mass spectrometry as a powerful and economically attractive global solution 
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1. Introduction 
Mass screening of populations for infection in epidemics, but particularly pandemics, requires 
clinically effective (high sensitivity and selectivity) testing methods, requiring minimally-invasive 
sampling techniques, with fast turnaround (low hours) and a low cost of analysis (<1 USD)—a key 
feature in the context of large-scale screening of populations and the need for differential diagnosis 
of other circulating common cold pathogens. 
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Indeed, when the need for large-scale screening is global, logistical challenges such as the 
technical manpower, expertise, equipment and reagent availability and cost of the frontline test are 
less surmountable for most economically challenged countries facing the pandemic, rendering 
control of the epidemic in many regions beyond reach. 
Currently, RT-PCR testing is at the frontline for the identification of SARS-CoV-2 RNA. SARS-
CoV-2 RNA is generally detectable in upper respiratory swabs and bronchoalveolar lavage (BAL) 
samples during the acute phase of infection. Positive results are indicative of the presence of SARS-
CoV-2 RNA; while clinical plasma biomarkers such as D-dimer, CRP, IL-6 levels with patient history 
are necessary to determine the patient’s clinical COVID-19 status and level of therapeutic 
intervention. 
The 2020 global pandemic caused by the novel coronavirus SARS-CoV-2 pandemic has created 
an enormous challenge for health systems, clinical laboratories, public health intervention strategies, 
and community control measures worldwide. Testing limitations, including reagent shortages, 
remain a bottleneck in the battle to curtail COVID-19 spread in even the wealthiest countries [1,2] 
The development of new matrix-assisted laser desorption time-of-flight mass spectrometry 
(MALDI-ToF MS) diagnostics for SARS-CoV-2 detection is driven by the need for greater diagnostic 
capacity and alternative applications to complement standard PCR and antibody-based diagnostics. 
2. Materials and Methods 
2.1. Rational Design 
Preparative design in the development of any new assay system can circumvent many of the 
inevitable hurdles and dead ends that are encountered in early studies that have high promise, but 
have not considered detailed real-world characteristics. These include sampling errors, pathogen 
biology, biochemistry and physical limitations of the technology; not to mention, due regard for 
bioinformatic rigor needed for classification and identification of robust and relevant markers. This 
has often been observed in the field of mass spectrometry, following sweeping assumptions and 
unrepresentative standards. However, rational multi-discipline-based approaches to address these 
challenges, with step-by-step robust tests can result in significant diagnostic and socio-health 
economic returns [3]. 
To develop MALDI-ToF MS-based diagnostics to specifically identify SARS-CoV-2, while 
distinguish this pathogen from other respiratory viruses, we had to overcome hurdles in the initial 
stages, looking beyond the traditional approaches which used established protocols routinely 
employed for bacterial identification [4]. 
2.1.1. Viral Biological Target for Detection by MALDI-ToF 
Enveloped viruses have the unique biological feature of utilizing the host cell membrane as the 
outer coating covering the core containing the RNA genome. The coronaviruses have 4 major 
structural envelope proteins and a large number of important functional proteins coded by their 
genome (Figure 1). Key amongst these viral envelope proteins are the Spike protein encompassing 
the receptor binding domain (RBD) and membrane fusion complex, domains that enable infection of 
target host cells. For the coronaviruses, these have been termed Spike or “S” proteins (see Figure 1a). 
Large trimeric complexes, these contain functional regions that undergo, what has been described as, 
tectonic conformational changes upon receptor binding and triggered exposure of membrane fusion 
peptide sequences [5,6]. These bring the viral envelope and target cell lipid bilayer membrane into 
close contact such that fusion can occur. Only a minor pore is sufficient for the viral RNA to enter 
and be expressed (Figure 1b). Early-phase ORF expression takes control of the cell machinery, 
circumventing cellular defences such as ribonucleases and ubiquitination of viral proteins. Late-
phase ORF expression makes more viral envelope proteins, nucleoprotein and Spike complex 
transcribed and post-translationally modified by the host cells endoplasmic reticulum and Golgi 
apparatus. Together with the viral RNA genome, these are packaged into membrane exosomes to 
form enveloped virions bristling with spike protein complexes (see Figure 1b,c).  
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Figure 1. Molecular cellular pathology of SARS-CoV-2 infection: Panel (A) Schematic Illustration of 
SARS-CoV-2 viral RNA genome in relation to order of expression and functional incorporation with 
the Virion particle. The genome comprises a 5′-untranslated region (5′-UTR), open-reading frames 
(ORFs) 1a and 1b encoding nonstructural proteins 3-chymotrypsin-like protease (3CLpro), papain-
like protease (PLpro), helicase (Hel), and RNA-dependent RNA polymerase (RdRp) as well as 
accessory proteins, and the structural S protein (S), E protein (E), M protein (M), and Nucleocapsid 
protein (N) in ORFs 2,4,5 and 9. Panel (B). Schematic of virion fusion mediated by Spike protein 
attachment to the ACE2 receptor and accessory cleavage of the Spike protein quaternary complex, 
resulting in fusion peptide exposure and binding to target cell plasma membrane. Focal, host cell and 
viral envelope lipid bilayer membrane fusion and viral RNA ingress of the target host cell. Shedding 
of Nucleocapsid and early ORF expression to take control of the cell and inactivate internal anti-viral 
proteins (e.g., Ubiquitin and RNase). Late ORF expression: replication of viral RNA genome and 
expression of, via post-translational processing mechanisms of the endoplasmic reticulum and Golgi 
apparatus (e.g., glycosylation), membrane embedded proteins that are responsible for infectivity 
including the Spike protein complex. Copies of SARS-CoV-2 vRNA are packaged into lipid bilayer 
membrane envelopes containing multiple copies of S, E, M and N, glyco- and phospho- proteins. 
Inclusion transport vesicle, packed with enveloped virions, fuses with host cell membrane releasing 
infective SARS-CoV-2 virion. Panel (C). Electro micrographs of multiple virions attacking the cell 
membrane (i), viral genome expression subsuming all functions of the cell to form thousands of virion 
copies within inclusion vesicles (ii) and finally release of multiple virions by fusion of inclusion 
packaging vesicles with the cell surface plasma membrane of the infected host cell (iii). Original 
composite figure adapted in parts from Depfenhart et al. [7] Kupferschmidt and Cohen [8] and Mason 
[9]. Scale bar: 1000 nm 
2.1.2. Optimisation of MALDI-ToF Matrix for the Identification of SARS-CoV-2 and Other Envelope 
vIrus Embedded Membrane Proteins 
In MALDI-ToF mass spectrometry for bacterial identification, the measured signals represent 
intracellular proteins, mostly highly abundant ribosomal proteins. The mass range usually measured 
ranges from 2000 to 20,000 Th; the proteins revealed are largely not glycosylated, although they may 
be post-translationally modified in other ways such as phosphorylation [10]. The most appropriate 
robust and widely used matrix for ionisation of such unique or characteristic microbial intracellular 
proteins is alpha-cyano-4-hydroxycinnamic acid (CHCA) [11]. 
In consideration of a MALDI-ToF MS test for virus detection, this mass range is unsuitably low; 
significant differences in virion particles include the absence of intracellular “housekeeping” 
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proteins. The majority of the unique features of viral proteins observed in MALDI are much larger 
(10,000–300,000 Th). Furthermore, many of the virus-specific proteins are heavily glycosylated [12] 
and post-translationally modified. This mass range is outside the effective limits for CHCA; other 
matrices have been shown to be more suited for the MALDI detection of large and glycosylated 
proteins [13]. 
Our method development investigated alternative matrices but sinapinic acid (SA) (3-(4-
hydroxy-3, 5-dimethoxyphenyl) prop-2-enoic acid) proved to be the most consistent and versatile 
and was used in all subsequently developed protocols. 
2.1.3. Sampling, Sample Handling 
Currently, sampling for COVID-19 screening in frontline testing is via nasopharyngeal and or 
oropharyngeal swabs, often an unpleasant experience for the individual being tested and a potential 
reason for poor compliance within regular testing regimes, particularly amongst children [14]. 
Once taken, the swab sample has to be made safe for handling by medical, transport and 
laboratory staff. Current methods inactivate virus by destroying proteins and the viral envelope 
membrane, preserving nucleic acid. Generally, nasal-pharyngeal swabs are either heat inactivated, 
disrupting the protein and viral envelope membrane, or stored in a transport media containing SDS 
and or Triton which destroys the viral envelope of the virus, but is detrimental to mass spectrometric 
detection methods [15]. 
For effective MALDI-ToF MS COVID-19 testing, based on detection and quantification of viral 
proteins, clinical sample deactivation has to largely do the opposite, i.e., preserve viral membrane 
and proteins but destroy the functional nucleic acid. This is conveniently achieved by the irradiation 
of sample tubes with UV-C, for as little as 15 min, to ensure safe handling in the laboratory and by 
transport systems [13]. 
Consequently, studies where swab samples have been split for simultaneous analysis by RT PCR 
detection systems of SARS-CoV-2 RNA and by MALDI-ToF mass spectrometry for viral proteins, are 
compromised [4]. 
As an alternative to swabs, saliva and/or gargle is an acceptable, and more easily obtained 
sample means of collection; 10 mL of water was found to be the optimum collection volume and 
media for gargle saliva testing. 
2.2. Enrichment of Viral Proteins Within the Analyte Sample 
Whether viral culture media, saliva/gargle, serum or urine, an enrichment of the target (e.g., 
viral Envelope proteins), by the removal of unwanted entities is often necessary to improve mass 
spectrometric detection. The presence of abundant host molecules (such as albumin) can not only 
mask key, less abundant target proteins, but also suppress the ionisation of other low abundance 
proteins, even if they are detected at a distant m/z. Not only does enrichment, and clean-up improve 
the detection of lower abundance signals, but also improves shot-to-shot and sample-to-sample 
reproducibility [16,17]. 
In this work, the sample clean-up exploited the biophysical size difference, of several orders of 
magnitude, between virion particle and most components of acellular fractions of human biological 
fluids, allowing the convenient separation of them by precipitation. Separation by ultracentrifugation 
was ruled out as impractical for routine implementation, as was selective precipitation by salt 
addition or PEG, due to their deleterious impact on MS analysis. Acetone precipitation, using ice-
cold addition, was found to be the most effective means of reproducible, facile selective precipitation 
for MS analysis. Other assisted precipitation methods such salting out resulted in samples being 
contaminated with high concentration of ions that suppressed target protein matrix assisted 
ionisation; whilst Polyethylene Glycol (PEG) assisted precipitation resulted in multiple interfering 
polymer peaks in the resultant MS spectra. 
The optimised methodology for efficiency, speed a simplicity consisted of a 1 to 1 addition of ice 
cold acetone, spun in a refrigerated bench top centrifuge (4 °C) at 16,000× g for 30 mins. The 
supernatant (containing unwanted background proteins) is discarded and the pellet resuspended in 
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a membrane dissolution and viral envelope protein solubilisation buffer (Figure 2). Much higher 
ratios of acetone and lower temperatures are commonly used but many more moderate to small 
proteins co-precipitate as a result and interfere with the final diagnostic mass spectra [18]. 
Acetone is an ideal organic solvent for the purpose of virion enrichment for mass spectrometry 
as not only does its weaker hydrogen and dipole bonding destabilise the hydration cloud 
surrounding large molecules, leading to precipitation; but it conveniently evaporates at room 
temperature without leaving a residue. Other organic solvents, including ethanol, similarly effect a 
precipitation but leave a residue [19]. This may account for acetone precipitation/evaporation having 
no detrimental effect on subsequent MALDI-ToF MS analysis. In addition, acetone denatures the viral 
envelope such that any virus is rendered biologically inert, but without completely destroying its 
structure (Figure 2a) [20]. This is not the case for salting, PEG and even methanol co-precipitation 
enrichment of virion particles, where they have detrimental effects on ionisation and spectra, and 
have been shown to leave the virus biologically active with increased PFU potencies within the 
precipitation [21–23]. 
 
Figure 2. Process of virion enrichment within a biological sample and extraction/solubilisation of 
Spike (S) and other viral envelope protein for MALDI ToF MS analysis. Panel (A): Biological samples 
containing virus are mixed 1 to 1 v/v with ice cold acetone and centrifuged at 16,000× g for 30 min at 
4 °C. The supernatant containing smaller non-precipitated solutes is discarded. The pellet is enriched 
with viral particles and kept for analysis. Acetone treatment inactivates envelope virus by 
deformation and partial fragmentation of the viral envelope and embedded protein Structures A. 
Panel (B): The pellet is resuspended in 10 to 100 uL of MALDI -ToF Mass spectrometry compatible 
dissolution and solubilisation buffer. Termed LBSD-X this buffer does not suppress ionisation and 
contains a detergent at a concentration optimised to release viral envelope embedded proteins 
together with non-embedded viral proteins. It also contains Dithiothreitol (DTT) in order to further 
reduce disulphide bonds so that quaternary and tertial structures are fully disrupted and monomers, 
polypeptide chains and glyco-polypeptides are liberated for detailed mass analysis. 
2.3. Disruption of Viral Envelope and Solubilisation of Viral Proteins 
Comparable to the analytical challenge Laemmli faced in his pioneering development of SDS-
PAGE for viral protein analysis [24]; here, large complexes have to be disrupted and the viral proteins 
solubilised as free proteins to be seen by MALDI ToF Mass spectrometry (Figure 2b). Unfortunately, 
detergents such as SDS, Triton and CHAPS, although widely used in molecular biology, largely 
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suppress ionization [25] and rapidly build up as fouling components on both the primary lens and 
other internal components of the mass spectrometer (Supplemental Figure S1). 
A series of novel detergents which avoided ion suppression and reduced lens fouling properties, 
were developed for solubilisation of hydrophobic and viral membrane-bound proteins. The best 
performing formulation (data not shown), termed “LBSD-X” was adopted for all subsequent 
experiments. 
In addition to solubilisation and ionization, the size of the target (glyco) proteins has to be 
considered with respect to the measurement range of the mass spectrometers. In our case, best 
performance on the Shimadzu MALDI 8020 (Shimadzu-Kratos, Manchester, UK) was a maximum 
mass limit of 250,000 m/z. In more parallels to Laemmli’s work, reduction of disulphide bonds was 
necessary in order to completely disrupt the tertiary structure to component protein/peptide chains. 
The resultant protein-polypeptide chains and glyco-polypeptides chains, although large, being 
within the high resolution capacity of this bench top mass spectrometer. Dithiothreitol (DTT) is well 
tolerated by MALDI-ToF MS, does not suppress ionization and thus was incorporated in the matrix 
dissolution buffer formulation. 
3. Results 
3.1. Characterisation of Pseudo and Live Virus Spike Envelope Proteins by Mass Spectrometry 
An important concern in test development for an infectious agent and particularly highly 
contagious, life threatening virus, is safety. The SARS spike S protein, a unique target as a marker of 
the infection, could be used and titrated into a biological sample in order to develop an analytical test 
with no risk to the development team [26]. However, although several recombinant SARS CoV-2 viral 
proteins are available, these are not optimal as the starting material in development of a clinical mass 
spectrometry viral detection system. They fail to represent the true nature of the molecule as it exists 
in a real clinical analysis: The spike protein exist as a trimer of S proteins partially embedded within 
the viral envelope. It is extensively glycosylated and is also proteolytically cleaved to prime and 
activate it for receptor binding and then exposure of fusion peptide domains to allow ingress of the 
viral genome [8,27] (Figure 1a,b). Recombinant proteins do not reflect this context and structural 
complexity, both of which can complicate sample processing to achieve marker release and correct 
detection and quantification. 
Pseudo-virus are constructs whereby virion-like particles, consisting of viral envelope exosomes, 
are made in vitro; lacking the viral genetic material, as it is not replicated or incorporated, (see Figure 
3) [28]. These are ideal non-infectious starting material upon which to develop a viral protein mass 
spectrometry tests. SARS2 Spike protein, S, genetic sequences were inserted into a target host human 
cell line, Hek293; so that fully post-translationally modified, membrane-embedded viral proteins are 
expressed and tertiary structures are functionally intact. It was found that co-transfection with 
TMP322 was necessary for pseudo-virus vectors constructed to express the spike proteins as a 
functional ingress effector, i.e., fusion with a target cell (see Figure 3). Through optimisation of the 
MALDI-ToF MS method, we discovered that the S protein was cleaved into S1, S2b and S2a fragments 
although held together by disulphide bridges [29]. These fragments were then searched for in the 
cultures of live COVID-19 virus grown on Vero, African green monkey, cells and shed as functional 
virions into the culture media. Using the optimised protocol developed on pseudotype-virus 
cultures, the same spike fragments could be seen, S1 (79,000 m/z) being the most prominent (see 
Figure 3). 
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Figure 3. Mass spectral profiles of Pseudo Virus expressing SARS-CoV-2 Spike S protein grown in 
culture, SARS-CoV-2 virus grown in vitro and mass spectra of gargle/saliva spiked with culture media 
from cells infected with SARS-CoV-2: S proteolytic fragments S1 and S2 were seen in all preparations 
and S2b only in serum free samples. Viral envelope proteins (VEPs) became more prevalent in live 
virus culture and Ig light chains and IgA heavy chain were additional peaks found in gargle/saliva 
samples. HEK293T/17 cells were seeded into 6 well cell-culture plates and co-transfected after 24 h 
with p8.91 (gag-pol expression plasmid), pCSFLW (luciferase reporter plasmid), and a viral 
glycoprotein expression plasmid encoding the spike protein of either SARS-CoV-2. The transfection 
mixture was prepared in OptiMEM using FuGENE-HD as a transfection reagent; cell culture media 
was replaced prior to transfection. The cell supernatant was collected via syringe 48 h after 
transfection and filtered through a 0.45 µm filter to harvest the lentiviral pseudo-type particles [28]. 
Pseudo virus expressing post translationally modified and conformational function SARS S protein 
and live SARS-CoV-2 virus where grown in culture, under category 3 containment conditions, on 
Vero-Green Monkey cells. Virions present in the culture media were filtered (0.45 µm), acetone 
precipitated-enriched as described and all viral envelope proteins, including S protein fragments, 
extracted and solubilized using extraction formulation LBSD-X buffer and detected as mass peaks by 
MALDI ToF MS. Scale bar: 1000 nm 
Along with S protein fragments, other viral component protein peaks were identified as 
characteristic of virions and were prominent in the viral cultures. These other Viral Envelope Proteins 
(VEPs) were characterised by their molecular mass, particularly a group of middle to high mass range 
broad peaks, indicative of variable glycosylation, which we have termed vep26–28k, vep34K, vep39–
40K and vep45–47K. 
Collection of volunteer gargle/saliva was by signed, informed consent and the study was 
approved by the IRB of MAPSciences (MAP24MAY2020-00003) and NISAD, (EP1207122020- 
MAP001) on the 24th of May and 23rd of August 2020 respectively.  
3.2. Identification of COVID-19 in Salivary Gargle Samples 
Having confirmed the specific and secondary target MS signals, indicative of coronavirus, as S 
protein proteolytic fragments (primarily S1 and S2a) and VEPs; the effect of the gargle/saliva sample 
milieu was examined for sample matrix/potential detrimental effects on the spectra. One striking 
example of a negative sample matrix effect was clearly demonstrated by serum albumin, found in 
fetal calf serum (FCS) and used in supplementation of pseudo-virus and live virus cultures media; 
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the mass peak of which obscured detection of the similarly-sized S2b proteolytic fragment (Figures 3 
and 4). 
 
Figure 4. Clinical diagnostic protocol of gargle saliva collection, laboratory processing and spectral 
data features: Panel (A) illustrates patient (home) sampling gargling 10 mL of water and spitting that 
into a sample pot. Panel (B) illustrates rapid processing where received gargle sample is filtered 
through 1.2 and 0.45 mm filters, 5 mL is recovered and is acetone precipitated. The pellet is 
resuspended in viral envelope dissolution and protein solubilization buffer before being applied to 
MALDI ToF plates and analyzed (3 min per sample); output data being processed by appropriate 
software. Panel (C) illustrates a reference spectra of SARS-CoV2 grown in vitro with spectral pattern 
of viral envelope proteins (VEPs) and fragments of coronavirus spike protein labelled. Panel (D) 
illustrates overall spectra of 5 unscreened volunteer samples overlaid. The spectra from subject ID2 is 
indicated (blue line). Regions corresponding to mass ranges for VEPs and large characteristic 
fragments of the Spike protein are illustrated. These are illustrated in juxta position to gargle/salivary 
Immunoglobulin light chain and Ig A heavy chain peaks. Also to note that S2a fragment is surrounded 
by a host of high intensity/abundance proteins, the origins of which may be a mix of other co-enriched 
(bacterial) micro-organism from the oral cavity. An additional high molecular mass glyco-protein 
type peak was also seen at with a maxima at 112,000 m/z (marked **) was only seen in this sample. 
Saliva is a size-selective transudate of numerous serum proteins and organic biomolecules, often 
revealing these molecules at 10- to 100-fold lower concentrations than those found in serum [27]. 
Albumin is fortunately not normally found at any significant levels in saliva and S2b should be 
evident in COVID-19-positive gargle/saliva samples. However, other large molecules such as 
amylase and IgA are actively secreted into saliva and IgA has a very large mass of approximately 
360,000 daltons. Thus, large proteins, such as IgA, were co-precipitated in the acetone precipitation 
process described in this method, while the naturally free small- to medium-sized transudate and 
secreted proteins at lower masses, were removed in the supernatant. Similarly, any other micro-
organisms present in the sample, along with any other virus, would also co-precipitated from the 
oral/gargle/saliva wash. To minimise potentially interfering effects, all gargle/saliva samples were 
sequentially prefiltered with 1.2 and 0.45 μm syringe filters before acetone precipitation, retaining 
most large micro-organisms on the filter but allowing through virions and immunoglobulins. 
As a result of disulphide bond reduction, large-molecular-weight immunoglobulins were 
visualised in the mass spectra of saliva samples, resolving as heavy and light chains (Figures 3 and 
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4). Their presence did not detract from spectral detection of the S1, S2b fragments or VEPs, despite 
being significant components. 
However, by adding in live virus containing culture media to a control gargle saliva the analysis 
remained slightly compromised as a comparative testing model since BSA would always be present 
(Figures 3 and 4). 
3.3. Detection of COVID 19: Reproducibility, Sensitivity and Specificity 
To estimate sensitivity and specificity saliva/gargle (n = 10) was spiked with spent Vero cell 
culture media producing SARS-CoV-2 at a concentration of 104 to 105 PFU/mL. These were subject to 
MALDI-ToF mass spectrometry and the peak heights measured for the peaks of interest. Two RT-
PCR negative persons simultaneously provided gargle/saliva samples at the time of swab sampling. 
These confirmed PCR-negative gargle samples were analysed by MALDI-ToF mass spectrometry 40 
times; the measured peak intensities of which acted as comparative controls to the viral spiked 
saliva/gargle. Viral envelope protein peak intensities were clearly elevated in the spiked samples 
(Figure 5). Gargle/saliva was collected from 35 volunteers who did not have simultaneous COVID-
19 PCR determinations, although some suspected they had suffered from the infection but were 
recovered or recovering. The intensity of S protein fragments S1 (79,000 m/z), S2b (62,000-72000 m/z) 
(can be obscured by albumin if present) and S2a (13,500 m/z) were measured along with peaks masses 
thought to represent other viral envelope proteins (VEPs). The maximal intensity was measured for 
these broad glycoproteins peaks at 26,000–28,000 m/z (vep26–28K), 34,000 m/z (vep34K), 39,000–
40,000 m/z (vep39–40K) and 45,000–47,000 m/z (vep45–47K). 
S1 peaks showed clear elevation in levels for the SARS-CoV-2 virus culture spiked samples, 
being on average 102 x higher than the COVID 19 RT-PCR negative and volunteer gargle samples, 
where it was essentially not detected in 80% of samples. This marker alone could perform as a specific 
coronavirus MALDI ToF MS screening test with near 100% detection and specificity at 103–104 PFU 
SARS-CoV-2 virions in a 10 mL gargle/saliva sample. 
S2b peaks may also be another key indicator as, although undetectable in the culture media 
spiked samples due to interference from albumin present in the media from FCS. 
S2a peak intensity measures were more complicated. Although highly elevated in comparison 
to the control and random sample gargle/saliva group measurement was compromised as a peak of 
mass similar to that of S2b at 13,500 could be detected in a significant number of individuals. Many 
more peaks are seen in the lower mass range (below 20,000 m/z) of saliva/gargle sample and probably 
arise from the abundant housekeeping proteins of residual bacterial flora. This “S2a like peak” being 
of a similar mass may characterize a specific bacterial species. 
VEP protein peaks all showed elevated levels in the gargle/saliva spiked with SARS-CoV-2 
culture media. However, levels found in the control significantly overlapped, indicating these were 
not specific markers of COVID 19 but more generalised markers of virion membrane embedded 
proteins, reflecting their common importance to enveloped viruses. 
A notable sample from the volunteer group is that of sample ID2 which showed clearly elevated 
S1 and S2b, vep26–28k, vep34K, vep39–40K and vep45–47K and moderate elevated measurement of 
S2a. 
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Figure 5. Levels of proteolytic S protein fragments and viral-associated protein peaks in samples 
groups. Culture supernatant from Vero cells infected with Sars-Cov-2 were spiked into ten 
gargle/saliva samples at 1–10%. The viral load in these culture media was determined as at 104 to 105 
PFU/mL. Gargle/saliva were collected from two individuals, with and without a cough, who were 
confirmed as RT-PCR Covid-19 negative at the time of gargle/saliva collection. These were analysed 
20 times each. A series of 30 gargle/saliva was collected from volunteers, but COVID-19 PCR status 
at time of sampling was not known. These were analysed only once each. All samples were acetone 
precipitated, subjected to viral envelope protein solubilisation and analysed by MALDI-ToF mass 
spectrometry. Target peak intensities were then measured. Panel (A) illustrates the levels of each 
analysed sample for Spike protein fragment S1 peak at 79,000 m/z; panel (B) Spike protein fragment 
S2b at 63,000 m/z and panel (C) Spike protein fragment S2a at 13,500 m/z. The maximal intensity was 
also measured for broad glycoproteins peaks, considered to originate from other viral envelope 
proteins (VEPS), at 26,000–28,000 m/z (vep26–28K–panel (D)), 34,000 m/z (vep34K panel (E)), 39,000-
40,000 m/z (vep39–40K–panel (F)) and 45,000-47,000 m/z (vep45K–panel (G)). Red dots represent 
levels of peak intensity for the spiked gargle/saliva samples, orange dots represents levels of peak 
intensity for COVID-19 RT-PCR negative control 1 samples, grey dots represent levels of peak 
intensity for COVID-19 PCR negative control 2 samples and blue dots represent levels of peak 
intensity for unscreened volunteer gargle/saliva samples. Blue dots with red circle borders are the 
values recorded for volunteer subject ID2. 
3.4. Immunological Response and IgA Levels 
The local mucosal tissue barrier response to microbiological infection, including virus such as 
COVID-19, elicit secretion of IgA into the mucous and/or covering secretion such as tears and saliva 
(32). Peak masses matching that of Immunoglobulin light chains and the heavy chain of IgA were 
seen in the vast majority of gargle/saliva samples examined. IgA and IgG light chain are identical and 
that from IgM only slightly different on MALDI-ToF MS. However, the heavy chain of IgG, IgA and 
IgM are distinctly resolved on the MALDI-ToF mass spectrometer because of their different chain 
lengths. 
Only total Ig Light chains and IgA Heavy chains were seen in the gargle/saliva samples. The 
intensity of these were measured in order to evaluate any correlation with other marker peaks 
(excluded in the analysis were the culture media virus containing “spiked” samples-as levels here 
were not physiological and reflected that of the base control gargle/saliva). 
The levels of total Ig light chains were clearly differentiated between the two simultaneous 
COVID-19 RT-PCR negative control subjects. To note the higher levels seen in Figure 6a were also 
reflected in S2a-like (13,500 m/z) protein peak levels for the same person (Figure 5). Within the 
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subjects for whom COVID-PCR status had not been determined, the levels varied enormously from 
undetectable to the highest determined (Figure 6a). Subject ID2, the person with highest S1, S2b 
levels, had the third highest total Ig light chain levels. 
IgA heavy chain levels overlapped for samples from the two PCR-negative COVID-19 subjects 
and similarly, within the subjects for whom COVID-PCR status had not been determined, the levels 
varied enormously—from undetectable to the highest determined (Figure 6a). The highest level being 
seen in the sample from the person with the highest S1, S2b levels, subject ID2. 
It was noted that IgA heavy chains were only seen when elevated viral envelope proteins (VEPs) 
were detected in the mass spectra. To test a possible association, we plotted total Ig light chain and 
IgA heavy chain levels against the levels measured for individual VEPs. Total Ig light chain levels 
did not correlate with the levels of VEPs detected; but IgA heavy chain levels did for vep34K, vep39–
40k and vep45–47K (Figure 6b). 
 
Figure 6. Gargle/saliva Immunoglobulin protein levels. Panel (A) are plots comparing the total Ig light 
chain and total IgA heavy chain peak intensity levels for two COVID-19 PCR negatives control 
individuals (grey and orange dots respectively) repeated 20 times each (n = 40), versus the same peaks 
intensity level of 30 volunteers (blue dots) who gave gargle/saliva samples but whose COVID-19 PCR 
status was unknown at the time. Blue dots bound by a red circle are the levels of total Ig light chains 
and IgA heavy chains found in volunteer ID2. Panel (B) are scatter plots of total Ig light chains (upper 
plot) and IgA heavy chain peak intensities (lower plot) versus VEPs peak intensities for the 30 
volunteer gargle/saliva samples but whose COVID-19 PCR status was unknown at the time. No VEP 
level correlated with total Ig light chain level. Correlation were seen with Ig A heavy chain levels for 
vep39–40K (grey dots r2 = 0.60), vep44–47K (gold dots r2 = 0.53) and vep34k (orange dots r2 = 0.53) but 
not for vep26–28k (blue dots r2 = 0.06) 
4. Discussion 
Although simply applying the technique of MALDI-ToF mass spectrometry, as it has developed 
for identification of bacteria, for COVID-19 detection has been reported as promising [4], this 
approach is fraught with practical complications and analytical errors. Not least that the biochemistry 
focus that for bacterial identification the MALDI-ToF MS technique is optimized recognition of 
microbial pathogen hydrophilic, low to medium molecular weight, high abundance housekeeping 
proteins. SARS-CoV-2, an envelope virus, has little if any equivalent proteins and its virion contains 
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a high abundance of medium to large membrane associated/embedded (predominately hydrophobic) 
glycoproteins. To develop and maximise a clinical efficient and cost-effective MALDI-ToF mass 
spectrometry screening solution for COVID-19 and future viral pandemic screening, requires rational 
design based on an understanding of the chemistry, biology and physics of the pathogen–host 
interactions and also their unique marker biomolecules. This is further complicated by how such 
chemistry and proteins behave in MALDI-ToF mass spectrometry. 
By targeting MALDI-ToF mass spectral detection to viral envelope glycoproteins, a 
multidisciplinary team approach has achieved a multifaceted clinically MALDI ToF MS screening 
test for COVID-19 and future such pandemics that may arise. Further validation in relation to PCR 
detection in patients is needed but the system described promises a multifaceted diagnostic tool as 
follows: 
1. Sensitive and specific identification of coronavirus in gargle/saliva by measurement of S1 and 
probably S2b protein peaks. 
2. Together with S1 and S2b, very high level of a peak at 13,500 m/z, presumed to be S2a, present 
in the in vivo sample is an additionally indicator of a coronavirus infection. 
3. More moderate elevation of S2a-like peak mass in the absence of elevated S1 and S2b peaks may 
be due to a similar protein/fragment arising from a microbiological infection of the oral 
respiratory tract, probably a bacterial housekeeping protein. 
4. Elevated levels of VEPs are markers of viral infection. 
5. Elevated levels of total Ig Light chain is indicative of an oral upper respiratory immune response. 
6. Elevated levels of gargle/saliva IgA heavy chain peak are indicative of viral infections. 
The final threshold for each component of the test are yet to be fully validated for computation 
software automation, but results are likely to be expressed as a heat map, the basic system being red, 
green and grey. The grey zone requiring retesting (see Figure 7). 
In our preliminary study of COVID-19 RT-PCR untested volunteer samples for surveillance-
screening, volunteer subject ID2 stood out with elevated levels in all markers. In their 30s, this 
individual worked in the music entertainment industry—they reported having been bed bound with 
Covid-19 symptoms, severe fatigue, loss of taste and smell and persistent cough in April (2020) 2 
months prior to giving a gargle/saliva sample. At the time of sampling, they reported to be 60–80% 
recovered from the symptom of fatigue which had persisted. In our follow-up, they gave another 
sample 14 days later and were also tested for COVID-19 by the NHS PCR service the same day. The 
analysis of the repeat sample showed no detectable coronavirus S proteolytic fragment protein peaks; 
total Ig light chains and IgA heavy chain levels had fallen dramatically but were still elevated (see 
Figure 7, ID44 *). The COVID-PCR result was reported as negative. 
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Figure 7. Illustration of clinical data output. Format is a heat map scoring of peak intensity relative to 
those values for SARS-2 coronavirus spike protein fragments and viral envelope proteins, measured 
in gargle/saliva containing 1–10% culture media of SARS-CoV-2 virus at 104 per ml PFU. Red 
indicating elevated, Grey indicating slight to moderate increase and Green indicating within normal 
range. Heat map associated with immunoglobulin intensities are based on the range found in the 
volunteers for which volunteer ID2 was identified as recovering from suspected COVID-19 infection. 
ID2 was repeated after 14 days and his scores are shown under ID44 *. 
4.1. Estimate of Test Costs 
Adopting a MALDI-ToF MS-based technology has had dramatic effects on reducing the costs in 
microbiological identification of infections and estimates have been as high as an 80% reduction 
overall [29]. A full evaluation of cost to achieve screening of millions in a population using this 
technique have to take into account discount on bulk orders. However, given that this system is 
generally reliant on extremely low volumes of generic reagents, the major cost is the purchase of the 
mass spectrometer. We have worked out, using a basic model, that mass spectrometry reagent 
analysis costs per test are less than $1 USD per sample. All the sample collection tubes and syringe 
filters associated in the process are more expensive, at approx. $5 per sample at retail prices. Ignoring 
the latter peripheral costs of initial sample handling, we estimate that when including paying the cost 
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of a mass spectrometer over 3 years of operation (at 100,000 samples a year per machine), the basic 
instrument-reagent analysis cost per sample is approximately $2 USD. 
5. Conclusions 
Validation studies against saliva/gargle spiked with cultured virus are on-going and the current 
study indicate a close to 100% sensitivity if measuring S1 peaks alone as the indicator of coronavirus 
infection. Direct comparison of the MALDI-ToF MS testing with RT-PCR detection of COVID-19 in 
clinical samples is needed. However, this MALDI-ToF MS technique cannot work on stored second 
sample Nasal-pharyngeal swabs as they will have either been heat inactivated (cooking the protein 
and viral envelope membrane) or stored in a transport media which contains SDS and/or Triton, 
which suppresses ionization and similarly destroys the viral envelope. In the absence of a freezer full 
of pre-collected 10 mL gargle/saliva for which RT-PCR results are known, only a prospective study 
is possible. This is in process. We are working with several groups to collect gargle/saliva samples at 
presentation where a swab for PCR testing is being taken simultaneously. These groups will analyse 
the sample on their MALDI-ToF mass spectrometer instruments and with all the technical support 
and necessary key reagents provided. As detailed, other markers measured in this technique may 
give further valuable clinical information such as other viral infections and magnitude of the mucosal 
humeral immune response. 
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